We would like to inform you of a temporary interruption to supply to a number of our APIDRA insulin preparations. This is due to a technical issue on the production line at the Sanofi manufacturing site in Frankfurt. This has not affected the quality of any of our insulins, but has caused a temporary interruption of production. There is no concern regarding Apidra itself, and our other insulins, Lantus and Insuman, are not affected at all.
To read the full story click here.